Contineum Therapeutics, Inc. - ROE
CTNM
Price:
$15.37
Market Cap:
$578.24M
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing of small molecules different therapies for neuroscience, inflammation, and immunology indications in the United States. The company’s lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and chronic pain. It also develops PIPE-307, a novel, small-molecule inhibitor of the muscarinic type 1 receptor for depression and relapse-remitting multiple sclerosis. The company was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November...[Read more]
Industry
Biotechnology
IPO Date
2024-04-04
Stock Exchange
NASDAQ
Ticker
CTNM
PE Ratio
[-7.88]
ROE
[-24.73%]
Current Ratio
[37.17]
Dividend Yield
[0%]
Enterprise Value
[570.10M]
Dividend History
The ROE as of August 2026 (TTM) for Contineum Therapeutics, Inc. (CTNM) is -24.73%
According to Contineum Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -24.73%. This represents a change of 295.61% compared to the average of -6.25% of the last 4 quarters.
Contineum Therapeutics, Inc. (CTNM) Historical ROE (quarterly & annually)
How has CTNM ROE performed in the past?
The mean historical ROE of Contineum Therapeutics, Inc. over the last ten years is -37.32%. The current -24.73% ROE has changed -33.75% with respect to the historical average. Over the past ten years (40 quarters), CTNM's ROE was at its highest in in the December 2023 quarter at 11.44%. The ROE was at its lowest in in the December 2022 quarter at -19.13%.
Average
-37.32%
Median
-33.44%
Minimum
-61.76%
Maximum
-21.34%
Contineum Therapeutics, Inc. (CTNM) ROE by Quarter and Year
Discovering the peaks and valleys of Contineum Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 31.16%
Maximum Annual ROE = -21.34%
Minimum Annual Increase = -45.85%
Minimum Annual ROE = -61.76%
| Year | ROE | Change |
|---|---|---|
| 2025 | -22.98% | 7.71% |
| 2024 | -21.34% | -36.20% |
| 2023 | -33.44% | -45.85% |
| 2022 | -61.76% | 31.16% |
Contineum Therapeutics, Inc. (CTNM) Average ROE
How has CTNM ROE performed in the past?
The current ROE of Contineum Therapeutics, Inc. (CTNM) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-25.92%
5-year avg
-37.32%
10-year avg
-37.32%
Contineum Therapeutics, Inc. (CTNM) ROE vs. Peers
How is CTNM’s ROE compared to its peers?
Contineum Therapeutics, Inc.’s ROE is greater than Mereo BioPharma Group plc (-81.25%), greater than Kyverna Therapeutics, Inc. (-81.87%), greater than Lexeo Therapeutics, Inc. Common Stock (-47.48%), greater than Silence Therapeutics plc (-121.71%), greater than AC Immune S.A. (-123.98%), greater than Alto Neuroscience, Inc. (-47.22%), greater than Aldeyra The (-57.34%), greater than Capricor Therapeutics, Inc. (-59.27%), greater than Candel Therapeutics, Inc. (-60.42%), greater than Amarin Corporation plc (-5.99%),
| Company | ROE | Market cap |
|---|---|---|
| -81.25% | $49.03M | |
| -81.87% | $461.13M | |
| -47.48% | $345.50M | |
| -121.71% | $525.24M | |
| -123.98% | $234.59M | |
| -47.22% | $977.37M | |
| -57.34% | $95.91M | |
| -59.27% | $226.15M | |
| -60.42% | $762.74M | |
| -5.99% | $297.85M |
Build a custom stock screener for Contineum Therapeutics, Inc. (CTNM) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Contineum Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Contineum Therapeutics, Inc. (CTNM) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Contineum Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Contineum Therapeutics, Inc.'s ROE?
How is the ROE calculated for Contineum Therapeutics, Inc. (CTNM)?
What is the highest ROE for Contineum Therapeutics, Inc. (CTNM)?
What is the 3-year average ROE for Contineum Therapeutics, Inc. (CTNM)?
What is the 5-year average ROE for Contineum Therapeutics, Inc. (CTNM)?
How does the current ROE for Contineum Therapeutics, Inc. (CTNM) compare to its historical average?